Novo Nordisk is rated a Strong Buy as it shifts to a high-volume, lower-price model, improving operational efficiency and leveraging AI for cost savings. Recent FDA approvals for Wegovy HD and Awiqli, along with a strategic partnership with OpenAI, support ongoing innovation and supply chain independence. Despite challenges like patent expirations and price pressures, the company's valuation remains attractive with a P/E of 12.29 and a free cash flow yield near 4.7%. Upcoming catalysts include growth in US Wegovy volumes, oral Wegovy rollout, potential share buybacks, and new obesity therapy developments.
Novo Nordisk reported a decline in adjusted sales and operating profit for Q1 2026, yet its obesity care segment, particularly the Wegovy pill, showed strong growth and outperformed competitors like Eli Lilly. The company benefits from patent protect...
At the American Diabetes Association conference, leading drugmakers like Eli Lilly and Novo Nordisk showcased new obesity treatments including advanced GLP-1 pills and shots promising greater weight loss and easier dosing schedules. Eli Lilly's exper...
Eli Lilly reported a strong Q1 2026 with revenue up 55.5%, driven by its obesity drug Mounjaro and new oral GLP-1 pill Foundayo, raising its full-year guidance. In contrast, Novo Nordisk saw a 4% adjusted sales decline, job cuts, and challenges inclu...
Novo Nordisk has experienced an IT security incident involving unauthorized access to some internal systems. The company is investigating with cybersecurity experts and has temporarily taken certain systems offline to protect its environment. While c...
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved Wegovy pill (semaglutide tablets) as the first daily oral GLP-1 treatment for adults with obesity or overweight with weight-related conditions. Based on the OASIS 4 trial,...
